Dianthus Therapeutics DNTH First Selected Antibody — Potential Milestone Payments Due
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept dnth:PotentialMilestonePaymentsDue.
The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dianthus Therapeutics's first selected antibody — potential milestone payments due.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dianthus Therapeutics's first selected antibody — potential milestone payments due?
- Dianthus Therapeutics (DNTH) reported first selected antibody — potential milestone payments due of $11M in Q1 2026.
- How has Dianthus Therapeutics's first selected antibody — potential milestone payments due changed year-over-year?
- Dianthus Therapeutics's first selected antibody — potential milestone payments due decreased by 0.0% year-over-year, from $11M to $11M.
- What does first selected antibody — potential milestone payments due mean?
- This metric represents the aggregate future financial obligations triggered by the achievement of specific clinical, regulatory, or commercial development milestones for the company's lead antibody candidate. These payments are typically owed to third-party licensors or research partners as the asset progresses through the drug development lifecycle. Monitoring these potential liabilities is essential for assessing the long-term capital requirements and the net economic value of the company's primary pipeline asset.